Content

Welcome to the CJU website » LOG IN

Details

Tadalafil: a new agent for erectile dysfunction
Department of Surgery, Division of Urology, St. Joseph's Health Centre, Lon
Feb 2003 (Vol. 10, Issue 11, Pages( 17 - 22)

Abstract

Text-Size + 

  • Oral phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile dysfunction are preferred by most men, and are recommended in guidelines as first-line therapy, because of convenience, high efficacy, and low rates of side effects. Tadalafil (Cialis™) is a new agent that has been studied in different patient populations. It has a different molecular structure than other PDE5 inhibitors, and a different pharmacologic profile that provides a longer period of effectiveness than other agents. This article will review clinical trials on tadalafil, to provide a comprehensive overview of its efficacy and safety.

Current Issue

October 2017, Vol.24 No.5
canadian journal of urology mobile

canadian journal of urology